Latest News about Biotech
Recent news which mentions Biotech
From Benzinga
Gilead's $42.5K Priced HIV Drug Could Be Made At Just $40 Annually, Campaigners Urge Company To Slash Price
July 24, 2024
From Benzinga
UK's NHS Prescribes Weight-Loss Drug Wegovy Less Than Expected Due To Service Shortages
July 24, 2024
From Benzinga
From Benzinga
Sage, Biogen Shelve Development Of Nervous System Disorder Drug After Data Disappoints
July 24, 2024
From Benzinga
From Benzinga
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
July 24, 2024
From Benzinga
Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
July 23, 2024
From Benzinga
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
July 23, 2024
From Benzinga
Britain's Drug Regulator Approves Novo Nordisk's Weight Loss Drug Wegovy To Cut Heart Disease Risk In Obese Patients
July 23, 2024
From Benzinga
The Wall That Can Withstand 1700°F And Cut $10B In Losses: Fire-Resistant Hempcrete Now Certified
July 23, 2024
From Benzinga
Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer Study
July 23, 2024
From Benzinga
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients
July 23, 2024
From Benzinga
EXCLUSIVE: Adial Pharmaceuticals Moves Forward To Second Cohort In Pharmacokinetics Study of AD04 For Alcohol Use Disorder
July 23, 2024
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free